It's a dual-action treatment because it acts on GLP-1 and GIP receptors
Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, et al
Think of it as the muscle cell sensing that it is well-hydrated and well-resourced, so it shifts toward building rather than breaking down
The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin
4.6 Strengths and Limitations Strengths of this trial were the randomized controlled design with direct comparisons between separate and combined exercise and GLP-1 RA treatment, the structured and monitored exercise program, high adherence to the interventions and low dropout rates, and that we employed objective validated tests to measure physical function, muscle strength, and cardiorespiratory fitness
Protection: Keep your needles in their original packaging until the moment you are ready to use them